Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it provides clinical-stage product, such as LLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors ; Claudin 18.2 for the treatment of gastric and pancreatic cancer; FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Period	Net Profit Margin
2018-12-31	N/A
2019-12-31	N/A
2020-12-31	N/A
2021-12-31	-472.99%
2022-12-31	-218214.10%
2023-12-31	-344489.47%
2024-12-31	-1170863.64%
2025-12-31	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALLO	$2.25	+0.00%	6.51M
3
4
5

Allogene Therapeutics Inc. (ALLO) Profit Margin

Profit Margin Data

Get Allogene Therapeutics Inc. Data in Excel

More ALLO Financial Data